Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17457735 | 1.00 | CHRM5 (0.38) | CHRM5CHRM3SIGMAR1ABCC1ALDH1A1 | |
| SCHEMBL17457720 | 0.96 | SIGMAR1 (0.38) | CHRM5CHRM3SIGMAR1ABCC1ALDH1A1 | |
| SCHEMBL16119427 | 0.96 | SIGMAR1 (0.38) | CHRM5CHRM3SIGMAR1ABCC1ALDH1A1 | |
| SCHEMBL21698365 | 0.92 | ABCC1 (0.32) | CHRM5CHRM3SIGMAR1ABCC1 | |
| SCHEMBL16119468 | 0.87 | SMYD3 (0.39) | ABCC1ALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL17457715 | 0.87 | SMYD3 (0.39) | ABCC1ALDH1A1KMT2AKDM4EPOLB | |
| SCHEMBL16100502 | 0.86 | ALDH1A1 (0.34) | ALDH1A1KMT2AKDM4EMAPTMEN1 | |
| SCHEMBL17465753 | 0.86 | ALDH1A1 (0.34) | ALDH1A1KMT2AKDM4EMAPTMEN1 | |
| SCHEMBL17465696 | 0.85 | ALDH1A1 (0.35) | ALDH1A1KMT2AKDM4EMAPTMEN1 | |
| SCHEMBL16100710 | 0.85 | ALDH1A1 (0.35) | ALDH1A1KMT2AKDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294248-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| US-9944658-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294248-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | CHRM5 4213/4885CHRM3 4549/4885SIGMAR1 3058/4885 |
| US-20160024121-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | CHRM5 4213/4885CHRM3 4549/4885SIGMAR1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.